In the GeparQuinto trial , @,@ patients were randomized to receive four cycles epirubicin/cyclophosphamide ( EC , @/@mg/m ( @ ) q@w ) followed by four cycles docetaxel ( D , @mg/m ( @ ) q@w ) each with ( ECB-DB ) or without ( EC-D ) bevacizumab ( B , @mg/kg q@w ) concurrent with chemotherapy .